Vaxess Technologies Awarded Grant for Development of the MIMIX

Vaxess Technologies Awarded Grant for Development of the MIMIX-Flu Broadly Protective Influenza Vaccine

Vaxess Technologies, Inc., an innovative biotechnology company developing the MIMIX smart release patch was awarded a fast-track Small Business Innovation Research Grant (SBIR) from the National Institute of Allergy and Infectious Diseases, (NIAID grant number 1R44AI142948 – 01A1) part of the U.S. National Institutes of Health (NIH).

Vaxess will receive up to a total of approximately $2.2 million over the course of the award if project milestones are met. Nearly 20 percent of the global population is infected by influenza viruses every year, leading to severe illness and hospitalization for millions of individuals. Despite the availability of influenza vaccines, their public health impact is limited due to suboptimal efficacy and challenges with patient compliance.

[Continue reading the full article on Cision PR Web website ]